Lundbeck/Otsuka's 5HT-6 Alzheimer's contender first to Phase III post?
This article was originally published in Scrip
Executive Summary
The first detailed Phase II clinical data for Lu AE58054, originator Lundbeck and partner Otsuka Pharmaceutical's novel candidate for Alzheimer's disease, are convincing enough for the firms to confirm plans for a pivotal Phase III trial later this year.